|Bid||86.04 x 800|
|Ask||86.10 x 1000|
|Day's Range||84.32 - 86.58|
|52 Week Range||78.95 - 116.49|
|Beta (3Y Monthly)||0.93|
|PE Ratio (TTM)||16.24|
|Forward Dividend & Yield||2.12 (2.36%)|
|1y Target Est||N/A|
GuideStone Capital Management President David Spika joins Yahoo Finance's Adam Shapiro, Julie Hyman, Jared Blikre, and MIT Professor Sinan Aral.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Quest Diagnostics Incorporated (NYSE:DGX) as an investment opportunity by taking the expected future cash flows and discounting them t...
Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics Inc NYSE:DGXView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderate for DGX with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on April 5. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding DGX is favorable, with net inflows of $27.79 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. DGX credit default swap spreads are near their highest levels of the last 3 years, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). We...
Rosenblatt Securities initiated Disney as buy Deutsche Bank initiated Dow Inc. as buy Deutsche Bank initiated Intuitive Surgical as buy Jefferies upgraded Lab Corp to buy from hold Jefferies upgraded Quest Diagnostics to buy from hold Deutsche Bank upgraded Hostess Brands to buy from holdHere are the biggest calls on Wall Street on Tuesday: Rosenblatt Securities initiated Disney as 'buy'Rosenblatt is bullish on Disney DIS 's direct-to-consumer strategy.
Quest Diagnostics' (DGX) partnership with UnitedHealthcare to operate as a preferred national laboratory seems strategic for the latter's customers.
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moody's Investors Service ("Moody's") assigned a Baa2 rating to the proposed offering of senior unsecured notes of Quest Diagnostics Incorporated ("Quest"). There are no changes to Moody's existing ratings of Quest including the Baa2 senior unsecured long-term rating. Further, Quest has a long track record of maintaining modest financial leverage and generating stable cash flows, which Moody's expects will continue.
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. And the truth is, you can make significantRead More...
Quest Diagnostics' (DGX) progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening are part of its recent major developments.
Quest Diagnostics Inc provides diagnostic testing, information, and services, providing insights that enable patients and physicians to make healthcare decisions. The dividend yield of Quest Diagnostics Inc stocks is 2.30%. Quest Diagnostics Inc had annual average EBITDA growth of 3.00% over the past ten years.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! It is not uncommon to see companies perform well inRead More...
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 0.00% and -2.42%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?